DoW Multiple Sclerosis Clinical Trial Award

Key Facts

Status: Forecasted

Posted date: May 5, 2026

Archive date: September 12, 2026

Close date: August 13, 2026

Opportunity ID: 362227

Opportunity number: HT942526MSRPCTA

Opportunity category: Discretionary

Agency name: Dept. of the Army -- USAMRAA

Agency code: DOD-AMRAA

Award floor: $0

Award ceiling: $0

Cost sharing required: No

Funding Instrument Types
  • Grant
Category of Funding Activity
  • Science and Technology and other Research and Development
Eligible Applicants
  • Unrestricted
Tools
Categories (use these for quoted searches)
  • agency_code:dod_amraa
  • category_of_funding_activity:science_and_technology_and_other_research_and_development
  • cost_sharing_or_matching_requirement:false
  • eligible_applicants:unrestricted
  • funding_instrument_type:grant
  • opportunity_category:discretionary
  • status:forecasted
Description

Summary: The fiscal year 2026 (FY26) Multiple Sclerosis Research Program (MSRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of multiple sclerosis. All applications must address at least one of the FY26 MSRP CTA focus areas. Clinical trials may evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance and/or emerging approaches and technologies.Distinctive Features: The FY26 CTA offers two funding levels. The following are generalized descriptions of the scope of research appropriate for each funding level:• Funding Level 1 (CTA-FL1) supports small-scale, proof-of-principle clinical trials (e.g., pilot, first-in-human, phase 0) to demonstrate feasibility or inform the design of more advanced trials, or other clinical trials that are appropriate for this funding level. Preliminary data relevant to the proposed clinical trial are required.• Funding Level 2 (CTA-FL2) supports larger-scale clinical trials at phase 1 or phase 2 that seek to show preliminary evidence of safety or efficacy (i.e., benefit of clinical or paraclinical outcomes) in relevant patient populations. Clear description and justification should be provided, which could include, but is not limited to, the intervention type, trial duration, sample size, outcome measures, assessment tools and frequency of assessment. Preliminary data relevant to the proposed clinical trial in MS populations are required.For the purposes of this funding opportunity, Regulatory Agency refers to the U.S. Food and Drug Administration (FDA) or any relevant international regulatory agency unless otherwise noted.

DoW Multiple Sclerosis Clinical Trial Award
Summary: The fiscal year 2026 (FY26) Multiple Sclerosis Research Program (MSRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of multiple sclerosis. All applications must address at least one of the FY26 MSRP CTA focus areas. Clinical trials may evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance and/or emerging approaches and technologies.Distinctive Features: The FY26 CTA offers two funding levels. The following are generalized descriptions of the scope of research appropriate for each funding level:• Funding Level 1 (CTA-FL1) supports small-scale, proof-of-principle clinical trials (e.g., pilot, first-in-human, phase 0) to demonstrate feasibility or inform the design of more advanced trials, or other clinical trials that are appropriate for this funding level. Preliminary data relevant to the proposed clinical trial are required.• Funding Level 2 (CTA-FL2) supports larger-scale clinical trials at phase 1 or phase 2 that seek to show preliminary evidence of safety or efficacy (i.e., benefit of clinical or paraclinical outcomes) in relevant patient populations. Clear description and justification should be provided, which could include, but is not limited to, the intervention type, trial duration, sample size, outcome measures, assessment tools and frequency of assessment. Preliminary data relevant to the proposed clinical trial in MS populations are required.For the purposes of this funding opportunity, Regulatory Agency refers to the U.S. Food and Drug Administration (FDA) or any relevant international regulatory agency unless otherwise noted.
[Forecasted] DoW Multiple Sclerosis Clinical Trial Award
Forecasted
Dept. of the Army -- USAMRAA
Science and Technology and other Research and Development
Grant
Unrestricted
2026-05-05